Profile

I joined Taylor English because it allows experienced lawyers who genuinely love the practice to provide top-quality services to their clients at an unparalleled value proposition.

Philip A. Theodore is a Partner in Taylor English’s Corporate and Business practice group. His practice centers on assisting public companies navigate the intricacies of the federal securities laws and the requirements of sound corporate governance. During his 40-year career, Mr. Theodore gained a unique perspective on the practice of law as a corporate partner at King & Spalding and as the general counsel of five public companies.  He is guided in his delivery of legal services to his clients by three core values:  responsiveness, practicality and decisiveness. 

Mr. Theodore’s experience spans a wide variety of industries, with a particular focus on the life sciences. He served as General Counsel for Serologicals Corporation (NASDAQ), John H. Harland Company (NYSE), Zep Inc. (NYSE), Aeterna Zentaris Inc.(NASDAQ) and Medizone International, Inc. (OTCQB). He regularly advises clients on corporate governance matters, negotiation of mergers and acquisitions, and ’33 and ’34 Act compliance. His career highlights include

  • Managing the legal aspects of a process to sell Zep to a private-equity firm, including negotiation of engagement letters with investment bankers and preparation of management-presentation materials;
  • Negotiating and closing Zep’s $120 million acquisition of the vehicle-care division of Ecolab Inc.;
  • Overseeing all legal aspects of the $1.7 billion sale of Harland, including preparing all ’34 Act filings for the transaction, including the proxy statement for the special meeting of Harland’s stockholders;
  • Overseeing all legal aspects of the $1.4 billion sale of Serologicals, including preparing all ’34 Act filings for the transaction, including the proxy statement for the special meeting of Serologicals’ stockholders;
  • Negotiating and closing approximately $325 million of acquisitions and dispositions for Serologicals;
  • Closing a $105 million underwritten offering of shares of Serologicals Common Stock;
  • Closing an offering of $130 million of Convertible Senior Subordinated Debentures for Serologicals;
  • Closing the $625 million registered exchange offer of debt securities for Magellan Health Services, Inc.; and
  • Overseeing the ’33 and ’34 Act aspects of the $1.2 billion ESOP leveraged buyout of Charter Medical Corporation and the subsequent prepackaged bankruptcy proceeding.

Newsroom

Alerts

Education

University of Cincinnati College of Law, JD, 1978

University of Tennessee at Chattanooga, BA, Political Science, magna cum laude, 1975

Bar Admissions

Georgia